Abstract 562P
Background
Existing literature supports the principle of early detection of colorectal cancer (CRC) via screening but has not definitively demonstrated an association between colonoscopy or polypectomy rates and CRC stage over time.
Methods
A longitudinal study was performed using the Australian national health database to obtain colonoscopy and polypectomy rates between 1998-2017. A second prospective database of CRC resection specimens was analysed for this period. The cohort was divided into three based on time intervals related to the national bowel cancer screening program: pre-commencement 1998-2006 (Period A), immediately post-commencement 2007-2011 (Period B), and subsequent years 2012-2017 (Period C).
Results
Annual colonoscopy rates doubled, and polypectomy rates tripled during the study (p<0.001). A total of 4506 patients underwent colorectal cancer resections. Annual colonoscopy rate correlated to a lower T-stage (p=0.038) and lower N-stage (p=0.026) leading to a 7% absolute (13.4% relative) increase in early CRC (stage I-II) in Period C (p<0.001). Across the study there was also a significant increase in right-sided tumours, and concurrent MMR deficiency and BRAF mutation.
Conclusions
Polypectomy and colonoscopy rates increased after the introduction of a national screening program which correlated to a clinically relevant shift to earlier CRC stages, a reduction in CRC incidence which manifested five years after implementation, and a reduced need for adjuvant chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
528P - Progression risk after pregnancy in patients with glioma
Presenter: Annette Leibetseder
Session: Poster session 10
529P - Post-marketing surveillance data from patients ≥70 years of age with central nervous system malignancies treated with Tumor Treating Fields (TTFields) therapy between 2011–2022
Presenter: Wenyin Shi
Session: Poster session 10
530P - Ultra low bevacizumab (BEVULTRA-100) as a novel approach in symptomatic management of high grade glioma: Can minimal dose make a difference?
Presenter: P ANURADHA
Session: Poster session 10
531P - Tumor treating fields therapy for glioblastoma: Identifying needs and satisfaction of new and long-term users
Presenter: Eleni T. Batzianouli
Session: Poster session 10
532P - Nitric oxide is a target by a combo-drug for glioblastoma treatment
Presenter: Manish Tripathi
Session: Poster session 10
533P - Oligodendrogliomas: What is the impact after the introduction of the WHO molecular classification?
Presenter: Maria Angeles Vaz Salgado
Session: Poster session 10
534P - Glioblastoma treatment in patients older than 60 years: Hypofractionated radiotherapy and temozolomide versus conventional radiotherapy and temozolomide
Presenter: Teresa Pacheco
Session: Poster session 10
535P - Hypofractionated radiotherapy in fit elderly patients with glioblastoma: Relevant or detrimental?
Presenter: Carla Martín Abreu
Session: Poster session 10
536P - Safety and efficacy of silibinin in patients with brain metastases after stereotactic radiosurgery (SRS): The SUSTAIN trial
Presenter: Niccolò Bertini
Session: Poster session 10
537P - S100A9 serum levels are associated with survival prognosis in patients with brain metastases
Presenter: Ariane Steindl
Session: Poster session 10